Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study

Category Primary study
JournalTransplantation and Cellular Therapy
Year 2021
This article has no abstract
Epistemonikos ID: dd1c83b811bdacf64a917fa585f4240dbf3fc3a0
First added on: Feb 14, 2025